Loading
Cancer's most important drivers, such as MYC and mutant p53, cannot be blocked with normal drugs. Pool effort and share results openly to build molecules that destroy them instead.
Targeted protein degradation (PROTACs, molecular glues) has produced clinical candidates for previously undruggable proteins, but efforts against the hardest targets are fragmented and duplicated under secrecy. Structural Genomics Consortium-style open science produced chemical probes for hundreds of proteins. The proposal is an open consortium with industry, academic and philanthropic members that generates and releases ligands, degraders, ternary complex structures and assays for the ten highest-value undruggable drivers (MYC, mutant TP53 variants, beta-catenin, KRAS G12D and rarer variants, fusion oncoproteins), with a pre-agreed rule that clinical candidates may be developed by any member.
Shares Kymera Therapeutics, Monte Rosa Therapeutics, AI-driven drug & target discovery, The undruggable drivers.
Shares Kymera Therapeutics, Monte Rosa Therapeutics, Secrecy and intellectual property block collaboration, The undruggable drivers.
Shares Kymera Therapeutics, Monte Rosa Therapeutics, AI-driven drug & target discovery, The undruggable drivers.
Shares Vogelstein, Lane and Levine 2000: surfing the p53 network, AI-driven drug & target discovery, The undruggable drivers, TP53.
Shares Secrecy and intellectual property block collaboration, AI-driven drug & target discovery, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Vogelstein, Lane and Levine 2000: surfing the p53 network, The undruggable drivers, TP53, KRAS.
Shares Kymera Therapeutics, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares The undruggable drivers, PROTACs & molecular glues (targeted protein degradation), TP53.